Skip to main content

Table 3A Clinical benefit achieved from 1st line endocrine therapy in all patients

From: "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer

Endocrine therapy

1 st line

N

223

N of CB (%)

159 (71.3%)

Median DOR with CB (months)

22+(7–117)

N still receiving treatment

50

  1. + = including patients who are still on treatment, therefore would have additional duration of response on a later analysis; CB = Clinical Benefit; DOR = Duration of Response
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us